Revenio Group
Revenio Group Corporation: Appointment to Revenio's Leadership Team (MFN)
Revenio Group Corporation, Stock exchange release, May 28, 2021 at 11.45
Appointment to Revenio’s Leadership Team
Dr Kate Taylor MBBS MPH, (b. 1971), Director of Eye Care Solutions, has been appointed to Revenio’s Leadership Team. She is the Co-Founder of Oculo, acquired by Revenio in April.
Kate is a medical doctor who initially trained as an ophthalmologist and holds an MPH from Johns Hopkins University as a Fulbright Scholar. She has worked in strategy, policy and advocacy with McKinsey & Company, the World Economic Forum’s Global Health Initiative, International AIDS Vaccine Initiative, and GlaxoSmithKline Biologicals.
Kate Taylor also serves on the Australian Digital Health Agency's Clinical and Technical Advisory Committee and the Australian Independent Hospital Pricing Authority. Previous board experience: (Australia) Mental Health CRC; (international) Roll Back Malaria, Stop TB, and the GAVI Alliance.
As of May 28, 2021, Revenio’s Leadership Team members are: CEO Jouni Toijala (chair), R&D Director of Imaging Devices Giuliano Barbaro, Operations Director Ari Isomäki, Sales and Marketing Director Tomi Karvo, CFO Robin Pulkkinen, R&D Director of Tonometers Mika Salkola and Director of Eye Care Solutions Kate Taylor, and QA Director Heli Valtanen.
Revenio Group Corporation Plc
Board of Directors
For further information, please contact:
CEO Jouni Toijala, tel. +358 50 484 0085 jouni.toijala@revenio.fi
CFO Robin Pulkkinen, tel. +358 50 505 9932 robin.pulkkinen@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA) Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a global leader in ophthalmological devices and solutions. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, Revenio Group’s eye care software platform Oculo combines clinical communication, telehealth, remote patient monitoring and data-analytics capabilities.
The Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy, and Oscare Medical Oy.
In 2020, the Group's net sales totaled EUR 61.1 million, with its operating profit standing at MEUR 17.1. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.